Recombinant
RabMAb

Anti-TRIF antibody [EPR18794] (ab180689)

Overview

  • Product name
    Anti-TRIF antibody [EPR18794]
    See all TRIF primary antibodies
  • Description
    Rabbit monoclonal [EPR18794] to TRIF
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IPmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Recombinant fragment within Human TRIF aa 500 to the C-terminus. The exact sequence is proprietary.
    Database link: Q8IUC6

  • Positive control
    • WB: HepG2, Ramos, HeLa, PC-12 and NIH/3T3 whole cell lysates; Human fetal lung, fetal heart and fetal kidney lysates; Mouse brain, heart and spleen lysates; Rat spleen lysate. IP: HepG2 whole cell lysate.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
  • Storage buffer
    Preservative: 0.01% Sodium azide
    Constituents: 59% PBS, 0.05% BSA, 40% Glycerol
  • Concentration information loading...
  • Purity
    Protein A purified
  • Clonality
    Monoclonal
  • Clone number
    EPR18794
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab180689 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 100 kDa (predicted molecular weight: 76 kDa).
IP 1/30.

Target

  • Function
    Involved in innate immunity against invading pathogens. Adapter used by TLR3 and TLR4 (through TICAM2) to mediate NF-kappa-B and interferon-regulatory factor (IRF) activation, and to induce apoptosis. Ligand binding to these receptors results in TRIF recruitment through its TIR domain. Distinct protein-interaction motifs allow recruitment of the effector proteins TBK1, TRAF6 and RIPK1, which in turn, lead to the activation of transcription factors IRF3 and IRF7, NF-kappa-B and FADD respectively.
  • Tissue specificity
    Ubiquitously expressed but with higher levels in liver.
  • Sequence similarities
    Contains 1 TIR domain.
  • Domain
    The N-terminal region is essential for activation of the IFNB promoter activity.
  • Post-translational
    modifications
    Phosphorylated by TBK1.
  • Information by UniProt
  • Database links
  • Alternative names
    • IIAE6 antibody
    • MGC35334 antibody
    • MyD88 3 antibody
    • Proline rich vinculin and TIR domain containing protein B antibody
    • Proline-rich antibody
    • PRVTIRB antibody
    • Putative NF kappa B activating protein 502H antibody
    • Putative NF-kappa-B-activating protein 502H antibody
    • Putative NFkB activating protein antibody
    • TCAM1_HUMAN antibody
    • TICAM 1 antibody
    • TICAM-1 antibody
    • Ticam1 antibody
    • TIR domain containing adapter molecule 1 antibody
    • TIR domain containing adapter protein inducing IFN beta antibody
    • TIR domain containing adaptor inducing interferon beta antibody
    • TIR domain-containing adapter molecule 1 antibody
    • TIR domain-containing adapter protein inducing IFN-beta antibody
    • Toll interleukin 1 receptor domain containing adapter protein inducing interferon beta antibody
    • Toll like receptor adaptor molecule 1 antibody
    • Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon beta antibody
    • TRIF antibody
    • TRIF protein antibody
    • vinculin and TIR domain-containing protein B antibody
    see all

Images

  • Lanes 1-3 : Anti-TRIF antibody [EPR18794] (ab180689) at 1/10000 dilution
    Lanes 4-6 : Anti-TRIF antibody [EPR18794] (ab180689) at 1/1000 dilution

    Lane 1 : HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate
    Lane 2 : Ramos (Human Burkitt's lymphoma cell line) whole cell lysate
    Lane 3 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate
    Lane 4 : Human fetal lung lysate
    Lane 5 : Human fetal heart lysate
    Lane 6 : Human fetal kidney lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    Lanes 1-4 : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
    Lanes 5-6 : Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution

    Predicted band size: 76 kDa
    Observed band size: 100 kDa (why is the actual band size different from the predicted?)



    Blocking/Dilution buffer: 5% NFDM/TBST.

    Exposure times: Lane 1-3: 5 seconds; Lane 4: 3 minutes; Lane 5/6: 10 seconds.

    The molecular weight  observed is consistent with what has been described in the literature (PMID: 20576118).

  • All lanes : Anti-TRIF antibody [EPR18794] (ab180689) at 1/1000 dilution

    Lane 1 : Mouse brain lysate
    Lane 2 : Mouse heart lysate
    Lane 3 : Mouse spleen lysate
    Lane 4 : Rat spleen lysate
    Lane 5 : PC-12 (Rat adrenal gland pheochromocytoma cell line) whole cell lysate
    Lane 6 : NIH/3T3 (Mouse embryonic fibroblast cell line) whole cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Predicted band size: 76 kDa
    Observed band size: 100 kDa (why is the actual band size different from the predicted?)



    Blocking/Dilution buffer: 5% NFDM/TBST.

    Exposure times: Lane 1-4: 10 seconds; Lane 5/6: 3 seconds

  • TRIF was immunoprecipitated from 0.35 mg of HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate with ab180689 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab180689 at 1/1000 dilution. VeriBlot for IP secondary antibody (HRP) (ab131366), was used as secondary antibody at 1/10000 dilution.

    Lane 1: HepG2 whole cell lysate 10µg (Input).

    Lane 2: ab180689 IP in HepG2 whole cell lysate.

    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab180689 in HepG2 whole cell lysate.

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 1 second. 

     

References

ab180689 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab180689.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up